Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bulent Yilmaz is active.

Publication


Featured researches published by Bulent Yilmaz.


Scandinavian Journal of Gastroenterology | 2016

Nutritional habits in functional dyspepsia and its subgroups: a comparative study

Zeynep Goktas; Seyfettin Köklü; Derya Dikmen; Omer Ozturk; Bulent Yilmaz; Mehmet Asil; Huseyin Korkmaz; Yaşar Tuna; Murat Kekilli; Evrim Karamanoğlu Aksoy; Hayretdin Koklu; Aslıhan Demir; Gülşah Köklü; Serab Arslan

ABSTRACT Objective: Research data demonstrating nutritional habits of functional dyspepsia (FD) patients are very limited. This is the first study to evaluate nutritional habits in FD subgroups according to Rome III criteria. Our aim was to evaluate nutritional habits of FD patients and determine the food items that may provoke a dyspepsia symptom. Methods: A total of 168 adults with FD and 135 healthy control subjects participated in the study. FD subjects were divided into epigastric pain syndrome (EP-FD), postprandial distress syndrome (PS-FD), mixed (MX-FD) subgroups according to Rome Criteria III. Subjects completed a questionnaire that included a short-form food frequency questionnaire. Furthermore, subjects were asked to list the food items that were causing a dyspepsia symptom. Results: Functional dyspepsia subjects had a slightly higher BMI (26.1 ± 4.97 kg/m2) than control subjects (24.6 ± 4.08 kg/m2). The most common symptom triggering foods among all the FD groups were fried and fatty foods (27.1%), hot spices (26.4%), and carbonated drinks (21.8%). In FD subgroups, carbonated drinks were more likely to cause a symptom in PS-FD group (37.3%) than MX-FD (25.7%) and EP-FD (22.1%) groups. There was no difference in frequency of main meals and snacks among any of the groups. Conclusion: Fatty and spicy foods and carbonated drinks were the most common symptom triggering food items in FD group. In subgroups, carbonated drinks and legumes were more likely to cause a symptom in PS-FD. Removing these food items during the course of treatment might help alleviate the symptoms.


Clinics and Research in Hepatology and Gastroenterology | 2016

The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis

Güray Can; Suleyman Ayvaz; Hatice Can; Ihsan Karaboga; Selim Demirtas; Hasan Aksit; Bulent Yilmaz; Uğur Korkmaz; Mevlut Kurt; Turan Karaca

BACKGROUND AND OBJECTIVE Ulcerative colitis is an inflammatory condition of the colon in the gastrointestinal system. Currently, the most potent medications used for ulcerative colitis produce no response in 20-30% of cases. There is a need for more efficient and reliable medications. Tyrosine kinase inhibitors have shown efficacy in some inflammatory diseases. Although dasatinib, a tyrosine kinase inhibitor, suppresses proinflammatory cytokines in colonic tissue, there are a few cases of hemorrhagic colitis with dasatinib. There is no study investigating the effect of dasatinib on experimental colitis. We aimed to investigate the effect of dasatinib in a colitis model induced with acetic acid in our study. METHODS In the study, 24 male Sprague-Dawley rats randomly distributed into 4 groups of 6 rats each as control, dasatinib, colitis and dasatinib+colitis groups. For colitis induction, 4% acetic acid was used. Sacrificing of the rats was performed on the seventh day. Disease activity, morphologic and histological injury, superoxide dismutase, myeloperoxidase and malondialdehyde activity, TNFα and CD3 expression were assessed in colonic tissue. RESULTS Apart from malondialdehyde, significant difference in all parameters between the control and colitis groups was determined. Difference between the colitis and colitis+dasatinib groups was not significant in only weight loss and biochemical parameters. Though dasatinib does not fully resolve the changes in colitis, there was significant regression. CONCLUSIONS Dasatinib decreased the inflammation in a rodent model of colitis. It may be provide this effect by the suppression of TNFα. Dasatinib may be one of the treatment options for ulcerative colitis.


Journal of Medical Virology | 2016

Fulminant hepatitis B as a result of reactivation in hematologic patient after rituximab therapy.

Bulent Yilmaz

With great interest, we read the recent article by Cho et al. [2016]. regarding the high titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma. The authors very clearly determined the predictive factors for rituximab-related HBV reactivation in resolved hepatitis B patients, defined as HBsAg-negative, anti-HBc-positive, and undetectable HBV DNA. We report a case of HBV reactivation in a 64-year-old anti-HBs-positive patient who received rituximab-based immunochemotherapy for Non-Hodgkin’s lymphoma (NHL). He had been treated with rituximab until 10 months ago. At the end of the treatment, the lymphoma was considered to be in complete remission. The patient was hospitalized with markedly elevated serum aminotransferase levels, jaundice, and coagulopathy. Clinical and biochemical evaluation provided criteria of acute liver failure: white blood cell count, 9.840/mm3; hematocrit, 40.4g/dL; platelet count, 125,000/mm3; prothrombin time, 31.3 seconds; international normalized ratio (INR), 3.62; AST level, 351 IU/L; ALT level, 503 IU/L; total bilirubin, 31.6mg/dL; direct bilirubin, 22.5mg/dL; albumin, 2.2 g/d; alkaline phosphatase (ALP), 99U/L; gamma-glutamyl transferase (rGTP), 141U/L; blood urea nitrogen (BUN), 94.6mg/dL; and creatinine (Cr), 2.45mg/dL and encephalopathy grade I. Acute liver failure was defined by King’s college criteria [O’Grady et al., 1989]. Briefly, virological analysis proved evidence of acute HBV infection (HBsAg-pos(665 IU/ml), anti-HBcAg-IgM-pos, HBeAg pos, viral load 7 107 IU/mL, anti-HDV-neg). There was no serologic evidence for recent infections with hepatitis A virus(HAV), hepatitis C virus (HCV), hepatitis D virus(HDV), herpes simplex virus (HSV), epstein-barr virus (EBV), and cytomegalovirus (CMV). Autoimmune marker analysis included anti-nuclear antibodies (ANA), smooth muscle antibody (SMA), liver kidney microsomal antibody type 1 (LKM-1), and all markers were found to be negative. Before her first therapy, hepatitis B virus (HBV) surface antigen was negative, while hepatitis B surface antibody (anti-HBs) was positive. However, a two year ago, he was HBsAg neg, anti-HBc IgG pos, and anti-HBs titer were 88,2 IU/mL. The patient has not been prophylaxed antiviral drug treatment during chemotheraphy. At 10 months after completing rituximab therapy, he developed hepatitis and HBV-DNA had changed to positive. Reactivation of HBV infection was considered and antiviral treatment with ETV 0.5mg daily was administered immediately. Then, the patient was referred to the liver transplantation center. He had oliguria unresponsive to fluid infusions. Renal ultrasound scan was normal, and urinary sediment was negative for hematuria, cylinders, or significant proteinuria. Type 1 hepatorenal syndrome(HRS) was suspected, and terlipressin plus albumin treatment was started. He died 3 days after HRS due to cardiac arrest. HBV reactivation in HBs antibody positive cases has also been reported [Dervite et al., 2001; Hui et al., 2006], and reactivation was reported in 3.4% of them [Salpini et al., 2015]. To summarize, we congratulate Cho et al. for their comprehensive report and would like to highlight the lack of clarity in the mechanism for rituximab-related HBV reactivation. We believe that antiviral prophylaxis might be essential for the patients with low baseline anti-HBs (<100mIU/ml).


Abant Medical Journal | 2015

Demographic evaluation of emergency department patients with mushroom poisoning

Bulent Yilmaz; Arif Duran; Mansur Kursad Erkuran; Ertuğrul Karğı; Güray Can; Tarik Ocak; Uğur Korkmaz; Mevlut Kurt

Özet Abstract Amaç: Bu çalışmada acil servise şüpheli mantar zehirlenmesi ile başvuran hastaların demografik ve klinik özelliklerini sunmayı amaçladık. Yöntem: Bu retrospektif çalışmada, Ocak 2007 ile Aralık 2014 tarihleri arasında Abant İzzet Baysal Üniversitesi İzzet Baysal Eğitim ve Araştırma Hastanesi Acil Servisinde görülen 648 hasta araştırıldı. Hastaların semptomları, demografik özellikleri ve mevsimsel değişimlerinin bilgileri analiz ettik. Bulgular: Acil servisten 648 hasta rapor edildi ve bunların% 60’ı kadındı. Ortalama yaşları kadın ve erkeklerde sırasıyla 39.7 ± 18.7 ve 41.3 ± 19.4 idi. Zehirlenmelerin çoğu sonbaharda( %51.4) ortaya çıktı. En sık başvuru şikayeti karın ağrısı %44.4 iken diğerleri sırasıyla; ishal %30.6, bulantı %9.3, iştahsızlık %9.3, kusma %5.6 ve halsizlik %0.9 idi. Sonuç: Mantar zehirlenmesi halen önemli bir ulusal sağlık problemidir. Bolu ili ve çevresinde mantar zehirlenmesi çoğunlukla 40 yaş altında ve sonbahar mevsiminde tanı konur. Hastaların çoğunluğu problemsiz taburcu edilmektedir. Objective: This study aimed to present demographic and clinical features of patients presenting with suspected mushroom poisoning to emergency department. Method: In this retrospective study, we investigated 648 patients who were seen at the Emergency Department of Abant Izzet Baysal University Izzet Baysal Education and Research Hospital from January 2007 to December 2014. We analyzed the data on the seasonal variation, demographic characteristics and symptoms of the cases. Results: Six hundred and forty-eight patients were reported to emergency department, where 60% of them were female. Mean age of female and male were 39.7 ± 18.7 and 41.3 ± 19.4 years, respectively. Most of the poisonings occurred in autumn (51.4%). Abdominal pain was the most common sign (44.4%) followed by diarrhea (30.6%), nausea (9.3%), anorexia (9.3%), vomiting (5.6%) and weakness (0.9%). Conclusion: Mushroom poisoning still remains as an important public health problem. Mushroom poisoning in Bolu and around were mostly diagnosed in patients younger than 40 years and in autumn. Most of the patients recovered without any problems. Anahtar Kelimeler: Acil servis, mantar zehirlenmesi, demografik.


Wiener Klinische Wochenschrift | 2015

Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis?

Emrah Posul; Bulent Yilmaz; Gulali Aktas; Mevlut Kurt


Gastrointestinal Endoscopy | 2014

Endoscopic removal of gastric bezoars: an easy technique

Mevlut Kurt; Emrah Posul; Bulent Yilmaz; Uğur Korkmaz


Bozok Tıp Dergisi | 2016

Listeria meningitis as a complication of adalimumab therapy in a patient with ulcerative colitis

Güray Can; Mevlut Kurt; Emrah Posul; Bulent Yilmaz; Uğur Korkmaz


Archive | 2015

Non-Invasive Predictors of Esophageal Varices in Patients with Chronic Viral Hepatitis associated with Cirrhosis Kronik Viral Hepatitlere Bağli Gelişen Siroz Hastalarinda Özefagus Varislerinin Non İnvaziv Prediktörleri

Güray Can; Bulent Yilmaz; Hatice Can; Sedat Alpaslan Tuncel; Hakan Genchellac; Gülbin Ünsal; Ahmet Tezel; Hasan Umit


Bozok Tıp Dergisi | 2015

Kronik Hepatit B Hastalarında İnsulin Direnci Sıklığı

Bulent Yilmaz; Gökhan Dindar; Ali Erkan Duman; Hasan Yilmaz; murat öztürkler; Uğur Korkmaz; Altay Celebi; Omer Senturk; Sadettin Hulagu


Journal of the Medical Sciences | 2014

Concomitant Leukocytoclastic Vasculitis and Nephrotic Syndrome in a Patient with Ulcerative Colitis

Güray Can; Ali Riza Soylu; Ahmet Tezel; Gülbin Ünsal; Bulent Yilmaz; Hatice Can; Hasan Umit

Collaboration


Dive into the Bulent Yilmaz's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Güray Can

Abant Izzet Baysal University

View shared research outputs
Top Co-Authors

Avatar

Emrah Posul

Abant Izzet Baysal University

View shared research outputs
Top Co-Authors

Avatar

Uğur Korkmaz

Abant Izzet Baysal University

View shared research outputs
Top Co-Authors

Avatar

Hatice Can

Abant Izzet Baysal University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cetin Boran

Abant Izzet Baysal University

View shared research outputs
Researchain Logo
Decentralizing Knowledge